Replimune stock.

Event to begin at 8:00 AM ETWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class ...We conduct our clinical trials with the highest possible standards. Replimune is also closely monitoring the ongoing COVID-19 pandemic to ensure patient safety. To download and learn more detailed information about Oncolytic Immunotherapy and RP1, click here. You can find more information about our ongoing clinical trials below.Mar 30, 2022 · Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone with payloads added to maximize immunogenic cell death and the ... Track Replimune Group Inc (REPL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsUnderstanding stock price lookup is a basic yet essential requirement for any serious investor. Whether you are investing for the long term or making short-term trades, stock price data gives you an idea what is going on in the markets.

Nov 13, 2023 · Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend.

Billionaires Julian and Felix Baker have been some of the best bio-stock pickers over the past 20 years. ... (CERS-3.09%), and Replimune Group (REPL 0.31%) in the most recent quarter. All three of ...Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.

Event to begin at 8:00 AM ETWOBURN, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of a novel class ...Aug 24, 2022 · Billionaires Julian and Felix Baker have been some of the best bio-stock pickers over the past 20 years. ... (CERS-3.09%), and Replimune Group (REPL 0.31%) in the most recent quarter. All three of ... Replimune ends selloff after FDA response to mid-stage cancer trial. Following four straight sessions of losses, oncology-focused biotech Replimune Group ( NASDAQ: REPL) added ~7% on Monday after ...

Dec 4, 2023 · Replimune Group Stock Performance. Shares of REPL stock opened at $11.71 on Monday. The company has a market cap of $691.58 million, a price-to-earnings ratio of -3.80 and a beta of 1.46. The stock has a 50 day simple moving average of $13.43 and a 200-day simple moving average of $18.08.

Woburn, MA. 51 to 200 Employees. Type: Company - Public (REPL) Founded in 2015. Revenue: Unknown / Non-Applicable. Biotech & Pharmaceuticals. Competitors: Unknown. Replimune is a biotechnology firm that develops oncolytic immuno-gene therapies to treat cancer. The powerful Immulytic™ platform combines multiple mechanisms to deliver …

Replimune will never request any financial information, funds, or passport details as part of the recruitment process. We employ a formal process that includes an interview with a member of our HR team. This is required and the only way to secure an employment offer from Replimune.Replimune Group Inc., headquartered in Woburn, MA, was founded in 2015 to develop the next generation of oncolytic immune-gene therapies for the treatment of cancer. Replimune is developing novel, proprietary therapeutics intended to improve the direct cancer-killing effects of selective virus replication and the potency of the immune …Nov 29, 2023 · The Replimune Group Inc. stock price fell by -1.34% on the last day (Wednesday, 22nd Nov 2023) from $10.43 to $10.29. During the last trading day the stock fluctuated 4.10% from a day low at $10.25 to a day high of $10.67. The price has fallen in 7 of the last 10 days and is down by -10.83% for this period. Replimune Group Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions. ... For US and Canadian Stocks, the Overview page includes key statistics on the stock's fundamentals, with a link to see more.Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of novel tumor-directed oncolytic immunotherapies.

Replimune Group, Inc. Common Stock (REPL) Earnings Report Date | Nasdaq. Created with Sketch. Zacks earnings numbers are reported on a BNRI (Before Non Recurring Items) basis and include stock ...We would like to show you a description here but the site won’t allow us.Nov 7, 2023 · About Replimune Replimune Group, Inc., headquartered in Woburn, MA, was founded in 2015 with the mission to transform cancer treatment by pioneering the development of a novel portfolio of oncolytic immunotherapies. Replimune’s proprietary RPx platform is based on a potent HSV-1 backbone intended to maximize immunogenic cell death and the ... Igniting a systemic immune response to cancer. Replimune’s mission is to revolutionize cancer treatment with therapies designed to activate a powerful and …Replimune Group, Inc. Stock price Equities REPL US76029N1063 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar …Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend.

Replimune Group, Inc. (NASDAQ:REPL – Get Free Report) saw some unusual options trading on Friday. Traders purchased 5,463 call options on the stock. This is an increase of approximately 87% ...

PURPOSE We evaluated the activity of intratumoral Coxsackievirus A21 (V937) in 57 patients with unresectable stage IIIC or IV melanoma. PATIENTS AND METHODS In this multicenter, open-label, phase II study, patients received up to a total V937 dose of 3 × 108 TCID50 (50% tissue culture infectious dose) in a maximum 4.0-mL …1,703.30 -8.20(-0.48%) Crude Oil 76.65 -0.52(-0.67%) Gold 1,943.70 +6.00(+0.31%) Replimune Group, Inc. (REPL) NasdaqGS - NasdaqGS Real Time Price. …Replimune | 9,469 followers on LinkedIn. Replimune's mission is to revolutionize cancer treatment with therapies designed to activate a powerful and durable full-body anti-tumor response.18 Sep 2023 ... at Replimune and Gilead also shared how they're accelerating ... Veeva (VEEV stock) Exceptional Business! SaaS Growth Stock for Life Sciences ...Nov 13, 2023 · Replimune Group Inc’s trailing 12-month revenue is $0.0 million with a % profit margin. Year-over-year quarterly sales growth most recently was %. Analysts expect adjusted earnings to reach $-3.531 per share for the current fiscal year. Replimune Group Inc does not currently pay a dividend. Replimune story: Exercise or conversion by Pamela Esposito of 25800 shares of Replimune subject to Rule 16b 3 and other headlines for Replimune GroupHe joins Ankyra from Replimune, where he served as the chief accounting officer and was responsible for financial, accounting, tax and human resources functions, and played a key role in the company’s successful 2018 initial public offering. Before Replimune, he served as vice president, finance and administration at uniQure. ...Earnings Summary. For their last quarter, Replimune Group (REPL) reported earnings of -$0.90 per share, missing the Zacks Consensus Estimate of -$0.80 per share. This reflects a negative earnings ...Find the latest Replimune Group, Inc. (REPL) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Nov 18, 2023 · Christopher has made over 1 trades of the Replimune Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Christopher sold 5,255 units of REPL stock worth $57,385 on 16 November 2023. The largest trade Christopher's ever made was selling 5,255 units of Replimune Inc stock on 16 November 2023 worth over $57,385.

Complete Replimune Group Inc. stock information by Barron's. View real-time REPL stock price and news, along with industry-best analysis.

Nov 21, 2023 · HC Wainwright dropped their price target on shares of Replimune Group from $50.00 to $48.00 and set a “buy” rating on the stock in a research report on Monday, November 13th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, Replimune Group has a consensus rating of “Buy” and an average price ...

Replimune's RPx platform, featuring RP1, RP2, and RP3, showcases a comprehensive and innovative approach to cancer treatment. Find out why REPL stock is a Buy.Dec 1, 2023 · 6 brokers have issued 12-month price objectives for Replimune Group's shares. Their REPL share price targets range from $34.00 to $70.00. On average, they anticipate the company's share price to reach $51.33 in the next year. This suggests a possible upside of 353.5% from the stock's current price. ... Stock REPL REPLIMUNE GROUP, INC. PDF Report. PDF Report : Replimune Group, Inc. Consensus Replimune Group, Inc. Equities. REPL. US76029N1063. Real-time Estimate ...REPL Stock 12 Months Forecast. $57.33. (396.79% Upside) Based on 4 Wall Street analysts offering 12 month price targets for Replimune Group in the last 3 months. The average price target is $57.33 with a high forecast of $70.00 and a low forecast of $42.00. The average price target represents a 396.79% change from the last price of $11.54.Nov 24, 2023 · The average price recommended by analysts for Replimune Group Inc is $48.44, which is significantly higher than the current market price. This suggests that there is room for the stock price to increase, according to analysts’ predictions. The company has also been involved in the development of a treatment for cutaneous squamous cell ... Replimune Group Stock Up 4.7 %. The stock has a 50-day moving average of $13.43 and a 200 day moving average of $18.09. The company has a market capitalization of $691.59 million, a PE ratio of -3 ...Item 1. Description of Registrant’s Securities to be Registered. A description of the common stock of Replimune Group, Inc. (the “Registrant”), par value $0.001 per share, to be registered hereunder is set forth under the caption “Description of capital stock” in the prospectus that constitutes a part of the Registrant’s Registration Statement on Form S …Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company’s proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively ...31 Jul 2023 ... Replimune will supply Incyte with RP1 for the study and share equally in the costs of the study. About RP1. RP1 is Replimune's lead oncolytic ...

Replimune Group Stock Performance. Shares of NASDAQ REPL opened at $11.71 on Monday. The company has a debt-to-equity ratio of 0.11, a current ratio of 12.76 and a quick ratio of 12.76.14 Des 2022 ... in its approximately $260 million public offering of 6,810,658 shares of common stock, inclusive of the underwriters' option to purchase ...18 Sep 2023 ... at Replimune and Gilead also shared how they're accelerating ... Veeva (VEEV stock) Exceptional Business! SaaS Growth Stock for Life Sciences ...Instagram:https://instagram. day to day trading apptesla stock buyday trade without 25kvalero renewables Replimune overview. Replimune, a subsidiary of Replimune Group Inc, is a pharmaceutical company that develops oncolytic immunotherapies for the treatment of cancer. The company’s pipeline products include RP1 used for the treatment of oncolytic immunotherapy backbone, and RP2 and RP3 for expressing anti-CTLA-4 and co … cruise ship runs agroundwhat is the best ai stock to buy Stock USD 19.28 0.44 2.23% Given the investment horizon of 90 days and your slightly conservative level of risk, our recommendation regarding Replimune Group is 'Hold'Feb 24, 2023 · Replimune Group, Inc. (REPL) has been beaten down lately with too much selling pressure. While the stock has lost 14.6% over the past four weeks, there is light at the end of the tunnel as it is ... btal etf BOSTON, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of a novel class of tumor-directed oncolytic immunotherapies, today announced the pricing of its public offering of 5,374,486 shares of its common stock at a public offering price of …Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added ...